Chimerix Inc
NASDAQ:CMRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Chimerix Inc
Free Cash Flow
Chimerix Inc
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Chimerix Inc
NASDAQ:CMRX
|
Free Cash Flow
-$75.3m
|
CAGR 3-Years
9%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-5%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Free Cash Flow
$17.8B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
1%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Free Cash Flow
$9.5B
|
CAGR 3-Years
4%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Free Cash Flow
$8.1B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Free Cash Flow
$3.2B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Free Cash Flow
$3.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
13%
|
CAGR 10-Years
19%
|
|
Chimerix Inc
Glance View
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Durham, North Carolina and currently employs 87 full-time employees. The company went IPO on 2013-04-11. The firm is focused on discovering, developing and commercializing medicines that address unmet medical needs. The firm offers TEMBEXA (brincidofovir) is an antiviral for the treatment of smallpox in all age groups, including infants, and for patients who have difficulty swallowing. The firm's product Imipridones is a cancer therapies, which provides ONC201 for brain and other cancers, ONC206 for central nervous system cancer and ONC212 for pancreatic cancer and leukemia. The Company’s DSTAT is a glycosaminoglycan derivative of heparin, which is a treatment for hematologic malignancies, including newly diagnosed acute myeloid leukemia (AML) in combination with standard chemotherapy.
See Also
What is Chimerix Inc's Free Cash Flow?
Free Cash Flow
-75.3m
USD
Based on the financial report for Dec 31, 2024, Chimerix Inc's Free Cash Flow amounts to -75.3m USD.
What is Chimerix Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
-5%
Over the last year, the Free Cash Flow growth was -9%. The average annual Free Cash Flow growth rates for Chimerix Inc have been 9% over the past three years , and -5% over the past ten years .
